Clinical labs are exploring new business opportunities as consumers take more control of their healthcare and bypass their doctors to initiate testing.

With the license, MeMed can offer its BV test, which is intended to distinguish between bacterial and viral infections, in Canada.

An initial $1.35 million has been deployed to the University of California, San Francisco, to initiate the program, with additional funding announcements forthcoming.

The test detects up to 25 viral and bacterial targets, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in one patient sample.

Labcorp said that the loan, which was provided by Wells Fargo and PNC, will be used for general corporate purposes.

Last week, readers were most interested in a story about Pluslife's MiniDock MTB, the only test in WHO's new class designation for tuberculosis diagnostic tests.

The firms, based in the UK and in France, are collaborating to develop an ELISA assay for a novel biomarker of severe sepsis known as oxidized pentraxin 3, or ox-PTX3.

The companies will work together to develop new antibody-based technologies for pathology and other applications.

After years of operating in the research markets, IDT has launched IVD assays based on the core chemistry capabilities from the company's Archer portfolio.

Intelligenome will contribute its testing platform to an NIH-funded program centered on cell-free DNA tuberculosis detection from respiratory and blood samples.

In February, the US Food and Drug Administration granted 510(k) clearance to a dozen in vitro diagnostic tests encompassing molecular, immunoassay, clinical chemistry, and ion selective electrode ...

The companies intend to reduce variability and rework by aligning high-quality slide preparation with reliable digitization.